Dr. Suresh Ramalingam
MD, FACP, FASCO
Executive Director, Winship Cancer Institute of Emory University
corporate_fareEmory Winship Cancer Institute, Atlanta, USA
Suresh Ramalingam
MD, FACP, FASCO
Dr. Suresh S. Ramalingam is a thoracic medical oncologist and Executive Director of Winship Cancer Institute of Emory University in Atlanta, Georgia. He specialises in lung cancer, including small cell lung cancer and non-small cell lung cancer, and holds the Roberto C. Goizueta Distinguished Chair for Cancer Research at Emory University School of Medicine.
Dr. Ramalingam completed his MBBS at Kilpauk Medical College in 1992 and his fellowship in haematology and oncology at the University of Pittsburgh Medical Center in 2003, the same year he received board certification in medical oncology from the American Board of Internal Medicine. He joined Emory in 2007 after faculty positions at the University of Pittsburgh School of Medicine and Wayne State University. His clinical and research focus covers precision oncology for lung cancer, EGFR-targeted therapy, immune checkpoint inhibitor research, and molecularly targeted clinical trials. He has authored more than 400 peer-reviewed publications, with over 36,000 citations and an H-index of 80, and serves as Editor-in-Chief of CANCER, a peer-reviewed journal of the American Cancer Society.
CancerFax can help international patients coordinate medical-report review and consultation support with Dr. Ramalingam's team at Emory Winship, subject to hospital availability and case acceptance.
Why Consider Dr. Suresh Ramalingam?
Dr. Ramalingam combines more than two decades of clinical expertise in lung cancer with a globally recognised research profile in EGFR-targeted therapy and immunotherapy, making him one of the most credentialed thoracic oncologists accessible through CancerFax.
Areas of Specialisation
Precision oncology for lung cancer, thoracic malignancies, and molecularly defined disease
Dr. Ramalingam's clinical and research practice centres on matching lung cancer treatment to tumour biology, molecular markers, and individual patient needs. His expertise spans small cell lung cancer, non-small cell lung cancer, EGFR-mutated disease, and thymic malignancies.
EGFR-Targeted Therapy & Precision Oncology
Molecularly guided treatment for EGFR-mutated non-small cell lung cancer, including third-generation EGFR inhibitor protocols.
- arrow_rightThird-generation EGFR inhibitor treatment planning for eligible patients
- arrow_rightBiomarker-driven selection of targeted agents based on tumour molecular profile
- arrow_rightManagement of EGFR-mutated NSCLC at advanced and unresectable stages
- arrow_rightMolecular profiling and individualised treatment planning
- arrow_rightIntegration of genomic data into systemic therapy decisions
- arrow_rightClinical trial–based treatment for molecularly defined lung cancers
Immunotherapy & Checkpoint Inhibitor Research
Clinical and translational immunotherapy research in lung cancer, including immune checkpoint inhibitor development and application.
- arrow_rightPD-1 and PD-L1 inhibitor protocols for eligible lung cancer patients
- arrow_rightClinical trial–based immunotherapy for NSCLC and SCLC
- arrow_rightTranslational research to improve immunotherapy outcomes
Small Cell & Non-Small Cell Lung Cancer
Comprehensive medical oncology for both major lung cancer subtypes, including advanced-stage and refractory disease.
- arrow_rightSystemic therapy for advanced, metastatic, and unresectable NSCLC
- arrow_rightTreatment planning following chemoradiotherapy for stage III disease
- arrow_rightPhase 1, 2, and 3 clinical trial participation for NSCLC
- arrow_rightMedical oncology for limited and extensive-stage SCLC
- arrow_rightMolecularly targeted agents and clinical trial options for SCLC
Thymic Malignancies
Specialist evaluation and treatment planning for thymoma and thymic carcinoma.
- arrow_rightMedical oncology management for thymoma and thymic carcinoma
- arrow_rightMultidisciplinary treatment planning within Emory Winship's thoracic programme
Procedures & Treatment Approaches
Medical oncology services and research-driven treatment planning for lung cancer
Dr. Ramalingam's clinical practice covers systemic treatment planning, targeted therapy, immunotherapy, and clinical trial–based care for patients with lung cancer and thoracic malignancies.
Lung Cancer Medical Oncology
Medical OncologyComprehensive systemic treatment planning for small cell and non-small cell lung cancer, tailored to tumour type, stage, and molecular profile.
EGFR-Targeted & Molecularly Guided Therapy
Targeted TherapyTargeted treatment for EGFR-mutated NSCLC and other molecularly defined lung cancers, using biomarker-driven agent selection.
Clinical Trial–Based Treatment
Complex DiseasePhase 1, 2, and 3 clinical trials using molecularly targeted agents and immunotherapy in small cell and non-small cell lung cancer, including investigational protocols at Emory Winship.
Multidisciplinary Lung Cancer Care
MultidisciplinaryCoordinated care planning with thoracic surgery, radiation oncology, radiology, and pathology teams within Emory Winship's NCI-designated cancer centre.
Second Opinion for Lung Cancer
Second OpinionExpert evaluation of existing lung cancer diagnoses, pathology findings, and treatment plans from patients seeking specialist review.
Research & Publications
Globally cited contributions to lung cancer clinical research and targeted therapy
Dr. Ramalingam has authored more than 400 peer-reviewed publications with over 36,000 citations and an H-index of 80. His work appears in The New England Journal of Medicine, The Lancet, Science, Nature, Journal of Clinical Oncology, and Journal of Thoracic Oncology. He serves as Editor-in-Chief of CANCER (American Cancer Society).
Dr. Ramalingam's full publication list is available on PubMed and Google Scholar. CancerFax can assist patients who wish to review his published research before requesting a consultation.
Education & Training
Dr. Ramalingam completed his medical education in India and undertook postgraduate training in internal medicine and haematology/oncology in the United States, receiving board certification in medical oncology in 2003.
Clinical Experience
Dr. Ramalingam joined Emory University School of Medicine in 2007 following faculty appointments at the University of Pittsburgh School of Medicine and Wayne State University. He has since risen to the most senior clinical and administrative leadership role at Winship Cancer Institute.
Languages & International
Dr. Ramalingam consults in English. Language details beyond English are not listed in reviewed official sources.
CancerFax can coordinate professional medical interpreter support for international patients seeking consultation at Emory Winship Cancer Institute.
CancerFax can coordinate professional medical interpreter support for international patients when required.
How CancerFax Helps You Access Dr. Suresh Ramalingam
CancerFax is a specialist cancer patient-navigation platform. We help international patients prepare structured medical summaries, assess treatment eligibility, and connect directly with Dr. Suresh Ramalingam's team — with full coordination from initial inquiry to consultation.
Medical Report Review
Free review of your pathology results, imaging, molecular profiling, and treatment history — prepared as a structured clinical summary for Dr. Suresh Ramalingam's team.
Treatment Eligibility Screening
CancerFax screens your case for eligibility for treatments and clinical programmes available through Dr. Suresh Ramalingam before you travel, so you arrive with a clear pathway.
Case Submission
We coordinate direct case submission to Dr. Suresh Ramalingam's department, including all documentation required for clinical review and appointment scheduling.
Appointment & Consultation Coordination
CancerFax manages appointment scheduling with Dr. Suresh Ramalingam's team, confirming availability and aligning timelines with your travel plans.
Travel, Visa & Logistics Support
We prepare visa invitation letters, provide hospital-proximity accommodation guidance, and coordinate airport transfers for international patients.
Follow-Up & Continuity of Care
After your consultation or treatment, CancerFax facilitates communication between Dr. Suresh Ramalingam's team and your home oncologist for seamless post-treatment follow-up.
Frequently Asked Questions About Dr. Suresh Ramalingam
Dr. Ramalingam specialises in lung cancer, including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), and EGFR-mutated lung cancer. Emory Winship Cancer Institute also lists thymoma and thymic cancer among his clinical specialties.
Dr. Ramalingam is the Executive Director of Winship Cancer Institute of Emory University in Atlanta, Georgia, USA — an NCI-designated cancer centre. He is also Associate Vice President for Cancer at Emory's Woodruff Health Sciences Center and Professor in the Department of Haematology and Medical Oncology.
Submit your medical reports — including pathology, imaging, molecular testing results, and prior treatment history — through CancerFax. The CancerFax team will review the documents, prepare the case, and coordinate with Emory Winship Cancer Institute, subject to availability and case acceptance.
CancerFax can assist international patients in coordinating medical-record review and consultation support with Dr. Ramalingam's team at Emory Winship. Availability and access depend on the hospital's international patient services and individual case assessment.
The LAURA Phase III trial evaluated osimertinib (a third-generation EGFR inhibitor) compared with placebo after chemoradiotherapy in patients with unresectable stage III EGFR-mutated non-small cell lung cancer. Results presented at ASCO 2024 and published in The New England Journal of Medicine showed significantly longer progression-free survival with osimertinib, establishing a new standard of care for this patient group.
Dr. Ramalingam has been practising oncology since 2003 — more than 22 years of experience. He has authored over 400 peer-reviewed publications with more than 36,000 citations and an H-index of 80. He serves as Editor-in-Chief of CANCER, the peer-reviewed journal of the American Cancer Society, and received the IASLC Paul A. Bunn, Jr. Scientific Award in 2023 for lifetime scientific contributions to thoracic cancer research.
Connect with Suresh Ramalingam Today
Share your medical reports for a free preliminary review. Our patient coordinators will help you understand your options and arrange a direct consultation.
Medical Disclaimer: Information on this page is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making any medical decisions.